Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5064 - Safety and efficacy of pazopanib (PAZ) in advanced soft tissue carcinoma (aSTS) by prior lines of therapy, age, and dose modifications: PALETTE subgroup analyses

Date

11 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Soft Tissue Sarcomas

Presenters

Axel Le Cesne

Citation

Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387

Authors

A. Le Cesne1, S. Bauer2, G.D.S. Demetri3, W.T.A. van der Graaf4, G. Han5, L. Dezzani5, Q. Ahmad5, H. Gelderblom6

Author affiliations

  • 1 Medical Oncology & Surgery, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 2 Dept. Of Medical Oncology, University Hospital Essen Westdeutsches Tumorzentrum, 45122 - Essen/DE
  • 3 Center For Sarcoma And Bone Oncology, Dana-Farber Cancer Institute and Ludwig Center, Harvard Medical School, 02215 - Boston/US
  • 4 Sarcoma Unit, The Institute of Cancer Research and the Royal Marsden Hospital , Sutton/GB
  • 5 Novartis Oncology, Novartis Pharmaceuticals, 07936-1080 - East Hanover/US
  • 6 Medical Oncology, Leiden University Medical Center (LUMC), Leiden/NL
More

Resources

Abstract 5064

Background

PALETTE was a randomized phase 3 trial (NCT00753688) that demonstrated single-agent activity of PAZ in advanced STS (aSTS). We evaluated the relationship between age, prior lines of therapy, and dose modifications on the safety and efficacy of PAZ in aSTS.

Methods

Median progression-free survival (mPFS) was evaluated in subgroups of prior lines of therapy (1 prior line; 2+ prior lines), age (

Results

A total of 246 patients received pazopanib in the PALETTE study. Median PFS and median overall survival (OS) were longer in patients receiving PAZ who had only 1 prior line of therapy vs 2+ prior lines of therapy (mPFS, 24.7 vs 18.9 weeks [Table]; OS, 13.7 vs 11.3 months). In patients receiving PAZ, mPFS was similar in ages

Conclusions

Longer mPFS was observed in patients receiving PAZ following only 1 line of therapy. Additionally, mPFS with PAZ was maintained regardless of patient age or if dose modification was required to manage toxicity.

Clinical trial identification

NCT00753688

Legal entity responsible for the study

Novartis Pharmaceutical Corporation

Funding

Novartis Pharmaceutical Corporation

Disclosure

A. Le Cesne: Pharmamar, Lilly, Pfizer, Novartis, Amgen. S. Bauer: Research support: Novartis, Blueprint Medicines, Ariad. Ad board: GSK, Novartis, Pfizer, Bayer, Fresenius, Lilly, Blueprint Medicines, Deciphera. CME-Honoraria: Pharmamar, GSK, Bayer, Novartis. Travel support: Pharmamar, Bayer. G.D.S. Demetri: Grants and personal fees from Novartis, during the conduct of the study; grants and personal fees from Janssen, Eisai, Eli Lilly and PharmaMar, outside the submitted work. W.T.A. van der Graaf: Research grants: GSK, Novartis. Advisory board: Bayer. G. Han, L. Dezzani, Q. Ahmad: Employee of Novartis. H. Gelderblom: Grants to institution LUMC, during the conduct of the study.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.